CXCR4 and plasma cell myeloma: BM-CAFs differentiation from BM-MSCs was also shown to be dependent on SDF-CXCR4 pathway in multiple myeloma (MM) (106, 107), while CXCR4 inhibitors (e.g., BL-8040) resulted in CAFs removal with promising clinical responses (108, 109).